Anosmin Antibody
| Code | Size | Price |
|---|
| PSI-6367-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6367-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Anosmin Antibody: HH1, HHA, KAL, KMS, ADMLX, WFDC19, KALIG-1, KALIG1, Anosmin-1, Adhesion molecule-like X-linked
Application Note:
Anosmin antibody can be used for detection of Anosmin by Western blot at 1 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Anosmin Antibody: Mutations in Anosmin-1, an extracellular matrix-associated glycosylated protein, have been linked with Kallmann Syndrome (KS), an X-linked genetic disorder characterized by loss of smell caused by abnormal olfactory bulb development and delayed puberty caused by disrupted migration of the gonadotropin-releasing hormone neuron. Anosmin-1 has been shown to directly bind FGFR1 via its N-terminal cysteine-rich domain, whey-acidic protein-like domain, and its first FnIII repeat with the D2 and D3 ectodomains of FGFR1. It is thought that Anosmin-1 can modulate FGFR1 signaling and have opposing effects on the formation and activation of FGF2-FGFR1-heparing complex.
Background References:
- Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991; 353:529-36.
- Soussi-Yanicostas N, Hardelin JP, Arroyo-Jimenez MM, et al. Initial characterization of anosmin-1, a putative extracellular matrix protein synthesized by definite neuronal cell populations in the central nervous system. J. Cell Sci. 1996; 109:1749-57.
- Hu Y, Guimond SE, Travers P, et al. Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein Anosmin-1. J. Biol. Chem. 2009; 284:29905-20
Buffer:
Anosmin Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Anosmin antibody was raised against an 18 amino acid synthetic peptide near the center of human Anosmin.
The immunogen is located within amino acids 430 - 480 of Anosmin.
The immunogen is located within amino acids 430 - 480 of Anosmin.
NCBI Gene ID #:
3730
NCBI Official Name:
Kallmann syndrome 1 sequence
NCBI Official Symbol:
KAL1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_000207
Protein GI Number:
119395746
Purification:
Anosmin Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
P23352
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SPT2 Peptide | PSI-6305P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|